Literature DB >> 9569997

Assessment of effect of food, gender, and intra-subject variability in the pharmacokinetics of avitriptan.

P H Marathe1, D S Greene, J S Lee, R H Barbhaiya.   

Abstract

The objectives of this study were to assess the effect of food and gender on the pharmacokinetics of avitripan. A group of 12 healthy men and 12 healthy women was administered a single 50 mg dose of avitriptan capsule under fasting conditions and 5 min after a high-fat breakfast. The two treatments were repeated in a replicate design to assess the intra-subject variability in the pharmacokinetics of avitriptan under fasted and fed conditions. There was a 1 week washout between treatments. Serial blood samples were collected over 24 h after dosing and analyzed by a validated HPLC method for avitriptan. The mean (SD) peak concentrations (Cmax) were 168 (86.4) ng mL-1 in the fasted condition and 57.3 (34.8) ng mL-1 in the fed condition in males and females combined. The corresponding areas under the plasma concentration curve (AUC) were 335 (162) and 185 (64.5) ng h mL-1, respectively. Both Cmax and AUC were significantly reduced in the fed condition. In addition, the time to peak concentration (tmax) was significantly delayed from a median of 45 min to 2 h after the high-fat breakfast. The clinical significance of this food effect is unclear at the present time. There were no gender differences nor a gender by food interaction in the pharmacokinetics of avitriptan. The intra- and inter-subject variability (%CV) in the Cmax and AUC of avitriptan in the fasted and fed conditions ranged from 10 to 60% in male and female subjects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9569997     DOI: 10.1002/(sici)1099-081x(199804)19:3<153::aid-bdd90>3.0.co;2-t

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  5 in total

1.  Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects.

Authors:  Julia Hanna; David J R Foster; Amy Salter; Andrew A Somogyi; Jason M White; Felix Bochner
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

Review 2.  How important are gender differences in pharmacokinetics?

Authors:  Bernd Meibohm; Ingrid Beierle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

4.  In vivo evaluation of the absorption and gastrointestinal transit of avitriptan in fed and fasted subjects using gamma scintigraphy.

Authors:  P H Marathe; E P Sandefer; G E Kollia; D S Greene; R H Barbhaiya; R A Lipper; R C Page; W J Doll; U Y Ryo; G A Digenis
Journal:  J Pharmacokinet Biopharm       Date:  1998-02

5.  Antimigraine Drug Avitriptan Is a Ligand and Agonist of Human Aryl Hydrocarbon Receptor That Induces CYP1A1 in Hepatic and Intestinal Cells.

Authors:  Barbora Vyhlídalová; Kristýna Krasulová; Petra Pečinková; Karolína Poulíková; Radim Vrzal; Zdeněk Andrysík; Aneesh Chandran; Sridhar Mani; Zdenek Dvorak
Journal:  Int J Mol Sci       Date:  2020-04-17       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.